600812.SHG North China Pharmaceutical Co Ltd
- Market cap
- CNY 8.30B
- P/E
- 96.8x
- P/B
- 1.45x
- ROE
- 1.6%
- Dividend yield
- 4.97%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 600812.SHG undervalued?
Graham number600812.SHG trades 149.9% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
North China Pharmaceutical Co Ltd fundamental analysis
No fundamental analysis for North China Pharmaceutical Co Ltd yet.
North China Pharmaceutical Co Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About North China Pharmaceutical Co Ltd
North China Pharmaceutical Company.Ltd engages in the research and development, production, and sale of pharmaceutical products in China and internationally. The company primarily offers anti-infective, biotechnology, and cardiovascular cerebrovascular drugs; and immunomodulators, vitamins, and health products. It also provides chemical, biological, agricultural, and biopharmaceuticals and veterinary drugs. It serves pharmaceutical distributors, agents, hospitals, chain phar…
Full company profileNorth China Pharmaceutical Co Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
North China Pharmaceutical Co Ltd annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 8.08B | 7.71B | 9.21B | 11.5B | 11.5B | 10.4B | 10.5B | 10.1B | 9.87B | 9.24B | 8.01B |
| Gross Profit | 1.51B | 2.37B | 3.78B | 4.70B | 4.09B | 3.69B | 3.44B | 3.21B | 3.14B | 2.87B | 2.11B |
| Operating Income | -14.0M | 104M | 205M | 265M | 184M | 136M | -568M | 156M | 312M | 666M | 439M |
| EBITDA | 633M | 858M | 1.01B | 1.29B | 1.22B | 1.22B | 1.35B | 1.28B | 1.46B | 1.66B | 507M |
| Net Income | 54.4M | 18.8M | 151M | 172M | 97.3M | 18.7M | -689M | 4.89M | 127M | 183M | 86.5M |
| EPS | 0.03 | 0.01 | 0.09 | 0.11 | 0.06 | 0.01 | -0.40 | 0.00 | 0.07 | 0.11 | 0.05 |
| Balance Sheet | |||||||||||
| Total Assets | 16.5B | 17.2B | 17.9B | 18.5B | 23.9B | 24.9B | 21.2B | 21.0B | 21.5B | 21.4B | 21.3B |
| Total Liabilities | 11.2B | 11.9B | 12.4B | 12.9B | 16.9B | 17.9B | 15.0B | 14.7B | 14.8B | 14.5B | 14.5B |
| Shareholders' Equity | 5.31B | 5.31B | 5.44B | 5.56B | 6.12B | 6.09B | 5.30B | 5.32B | 5.39B | 5.51B | 5.52B |
| Cash & Short-term Investments | 1.28B | 1.15B | 1.25B | 1.22B | 4.91B | 5.30B | 1.68B | 988M | 1.66B | 1.54B | 1.51B |
| Total Debt | 7.00B | 6.84B | 7.70B | 8.72B | 12.8B | 13.8B | 11.0B | 9.85B | 10.8B | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | -447M | 287M | 774M | 733M | 752M | 1.05B | 1.00B | 1.02B | 1.23B | 1.18B | - |
| Capital Expenditure | 289M | 400M | 507M | 646M | 1.01B | 547M | 550M | 623M | 784M | 542M | 502M |
| Free Cash Flow | -735M | -112M | 268M | 87.0M | -255M | 503M | 455M | 401M | 445M | 635M | 457M |
| Ratios | |||||||||||
| ROE | 1.0% | 0.4% | 2.8% | 3.1% | 1.6% | 0.3% | -13.0% | 0.1% | 2.4% | 3.3% | 1.6% |
| ROA | 0.3% | 0.1% | 0.8% | 0.9% | 0.4% | 0.1% | -3.2% | 0.0% | 0.6% | 0.9% | 0.4% |
| Net Profit Margin | 0.7% | 0.2% | 1.6% | 1.5% | 0.8% | 0.2% | -6.6% | 0.0% | 1.3% | 2.0% | 1.1% |
| Debt to Equity | 1.32x | 1.29x | 1.41x | 1.57x | 2.09x | 2.26x | 2.08x | 1.85x | 2.01x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
North China Pharmaceutical Co Ltd dividends
- Dividend yield
- 4.97%
- Forward dividend
- 0.04 CNY
- Payout ratio
- 225.5%
- Ex-dividend date
- Jun 11, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 413M | 0.24 | 225.5% |
| 2024 | CNY 469M | 0.27 | 369.4% |
| 2023 | CNY 499M | 0.31 | 10,195.2% |
| 2022 | CNY 103M | 0.06 | - |
| 2021 | CNY 48.9M | 0.03 | 261.3% |
| 2020 | CNY 48.9M | 0.03 | 50.3% |
| 2019 | CNY 48.9M | 0.03 | 28.4% |
| 2018 | CNY 520M | 0.32 | 345.3% |
| 2017 | CNY 409M | 0.26 | 2,180.9% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 15.68:10 on Aug 15, 2006.
Who owns North China Pharmaceutical Co Ltd
- Insiders 56.48%
- Institutions 0.55%
- Public & others 42.97%
- Shares outstanding 1.72B
- Free float 752M
North China Pharmaceutical Co Ltd company profile
- Company name
- North China Pharmaceutical Co Ltd
- Ticker
- 600812.SHG
- ISIN
- CNE000000D16
- Exchange
- Shanghai Stock Exchange
- Listed since
- Oct 12, 1993
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 9,972
- Fiscal year end
- December
- Address
- No. 388, Heping East Road, Shijiazhuang, China, 050015
- Phone
- 86 311 8621 9063
- Website
- ncpc.com
About North China Pharmaceutical Co Ltd
North China Pharmaceutical Company.Ltd engages in the research and development, production, and sale of pharmaceutical products in China and internationally. The company primarily offers anti-infective, biotechnology, and cardiovascular cerebrovascular drugs; and immunomodulators, vitamins, and health products. It also provides chemical, biological, agricultural, and biopharmaceuticals and veterinary drugs. It serves pharmaceutical distributors, agents, hospitals, chain pharmacies, and end-user clinics. North China Pharmaceutical Company.Ltd was founded in 1992 and is headquartered in Shijiazhuang, China.
North China Pharmaceutical Co Ltd management
5- Mr. Zhang MinVice Chairman & GM · born 1971
- Mr. Zhiguang XiaoChief Accountant, Secretary of Board of Directors & Director · born 1980
- Mr. Zhi Shan ChangDeputy General Manager · born 1971
- Mr. Rong Liang LiuDeputy General Manager · born 1973
- Mr. Zhi Gang DuanDeputy General Manager · born 1968